stockrow
Thursday 12 November 2026
Export INCY’s income statement to Excel — free account
Incyte Corporation
INCYIncyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.
- Revenue
- +14.0%
- EPS
- −277.9%
- Free cash flow
- −233.0%
- Total debt
- −10.5%
Quarter to September 2026, against a year earlier
121.89
0.38
−0.31%
Follow INCY
Alert me
Incyte Corporation (INCY) Shares outstanding
Incyte Corporation's shares outstanding at the end of fiscal 2025 was $200.7M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $203.2M. Over the past ten years it has ranged from $187.3M (fiscal 2015) to $225.9M (fiscal 2023); the current reading is higher than 27% of that period. Incyte Corporation ranks 48th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $200.7M | (4.67%) |
| FY2024 | $210.5M | (6.82%) |
| FY2023 | $225.9M | 0.88% |
| FY2022 | $224.0M | 0.85% |
| FY2021 | $222.1M | 1.83% |
| FY2020 | $218.1M | 0.19% |
| FY2019 | $217.7M | 0.94% |
| FY2018 | $215.6M | 5.40% |
| FY2017 | $204.6M | 5.39% |
| FY2016 | $194.1M | 3.64% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $203.2M | (2.39%) |
| Jun 2026 | $208.2M | 0.67% |
| Mar 2026 | $206.8M | 3.05% |
| Dec 2025 | $200.7M | (0.36%) |
| 43 more quarters | Free account |
Against its own ten years
Low $187.3M
High $225.9M
Ten-year median
$215.6M
Current reading's percentile
27
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $722.8M |
| GMAB Genmab A/S Sponsored ADR compare | $620.7M |
| EXEL Exelixis, Inc. compare | $255.8M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| INCY Incyte Corporation | $203.2M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.0M |
| ASND Ascendis Pharma A/S compare | $68.3M |
| JAZZ Jazz Pharmaceuticals PLC compare | $64.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement